Anti-colitis and -adhesion effects of daikenchuto via endogenous adrenomedullin enhancement in Crohn's disease mouse model (Q39625243)

13 September 2017

Anti-colitis and -adhesion effects of daikenchuto via endogenous adrenomedullin enhancement in Crohn's disease mouse model (English)

1 reference

13 September 2017

1 reference

Toru Kono

1

1 reference

13 September 2017

Atsushi Kaneko

2

1 reference

13 September 2017

Yoshiki Hira

3

1 reference

13 September 2017

Tatsuya Suzuki

4

1 reference

13 September 2017

Naoyuki Chisato

5

1 reference

13 September 2017

Nobuhiro Ohtake

6

1 reference

13 September 2017

Naoko Miura

7

1 reference

13 September 2017

Tsuyoshi Watanabe

8

1 reference

13 September 2017

26 November 2009

1 reference

Journal of Crohn's and Colitis

13 September 2017

1 reference

13 September 2017

4

1 reference

13 September 2017

2

1 reference

13 September 2017

161-170

1 reference

Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma

13 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

Adrenomedullin and adrenomedullin binding protein-1 downregulate TNF-alpha in macrophage cell line and rat Kupffer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

Acute and chronic responses associated with adrenomedullin administration in experimental colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

Biological and clinical roles of adrenomedullin in circulation control and cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

Exodus of Kampo, traditional Japanese medicine, from the complementary and alternative medicines: is it time yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

Dai-kenchu-to, a Chinese herbal medicine, improves stasis of patients with total gastrectomy and jejunal pouch interposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

The pharmacological effects of Daikenchuto, a traditional herbal medicine, on delayed gastrointestinal transit in rat postoperative ileus

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

The herbal medicine, Dai-Kenchu-to, accelerates delayed gastrointestinal transit after the operation in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

Effect of Dai-kenchu-to (Da-Jian-Zhong-Tang) on the delayed intestinal propulsion induced by chlorpromazine in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

Mechanism of atropine-resistant contraction induced by Dai-kenchu-to in guinea pig ileum

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

Mechanisms for contractile effect of Dai-kenchu-to in isolated guinea pig ileum

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

The preventive effect of Daikenchuto on postoperative adhesion-induced intestinal obstruction in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

The herbal medicine Dai-kenchu-to and one of its active components [6]-shogaol increase intestinal blood flow in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

Colonic vascular conductance increased by Daikenchuto via calcitonin gene-related peptide and receptor-activity modifying protein 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors: a comparison of effects of adrenomedullin22-52, CGRP8-37 and BIBN4096BS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

Postischemic infusion of adrenomedullin protects against ischemic stroke by inhibiting apoptosis and promoting angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

Calcitonin gene-related peptide in inflammatory bowel disease and experimentally induced colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

Adrenomedullin and mucosal defence: interaction between host and microorganism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

Bacteria- and host-derived mechanisms to control intestinal epithelial cell homeostasis: implications for chronic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

Regulation of adrenomedullin expression and release

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

Vasoactive hormone adrenomedullin and its binding protein: anti-inflammatory effects by up-regulating peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

Identification of novel adrenomedullin in mammals: a potent cardiovascular and renal regulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

Intermedin functions as a pituitary paracrine factor regulating prolactin release

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

Interfering with interferons in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

Interferon-gamma is a therapeutic target molecule for prevention of postoperative adhesion formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

Adrenomedullin and Proadrenomudullin N-Terminal 20 Peptide (PAMP) are Present in Human Colonic Epithelia and Exert an Antimicrobial Effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.09.006

10.1016/J.CROHNS.2009.09.006

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference